SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01464710

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Genetic Assessment of Early to Late macuLar dEgeneration studY 2

The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with early AMD (soft confluent drusen>120 microns ) in the study eye, and with either early AMD or advanced AMD in the non-study eye.

NCT01464710 Age-related Macular Degeneration
MeSH:Macular Degeneration

Primary Outcomes

Measure: To determine the allele frequency for patients that progress to bilateral advanced AMD in the study eye

Time: 5 years

Secondary Outcomes

Measure: To determine the allele frequency for patients that do not progress to bilateral advanced AMD in the study eye.

Time: 5 years
Time Perspective: Prospective

Cohort

There are 2 SNPs

SNPs

1 rs1061170

Genetic Assessment of Early to Late macuLar dEgeneration studY 2. Genetic Assessment of Early to Late Macular Degeneration Study The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with early AMD (soft confluent drusen>120 microns ) in the study eye, and with either early AMD or advanced AMD in the non-study eye.

2 rs11200638

Genetic Assessment of Early to Late macuLar dEgeneration studY 2. Genetic Assessment of Early to Late Macular Degeneration Study The purpose of this study is to determine if polymorphisms at rs11200638 on HTRA1 and rs1061170 on CFH are associated with an accelerated progression to advanced AMD (wet AMD or GA) in patients with early AMD (soft confluent drusen>120 microns ) in the study eye, and with either early AMD or advanced AMD in the non-study eye.


HPO Nodes